Ebrahim Mostafavi is currently at Stanford Cardiovascular Institute, Stanford School of Medicine. His research interests revolve around the use of cardiac iPS cells to design and develop in vitro models (organoids, vascular grafts, bioengineered tissues) for cardiovascular disease modeling and drug screening as well as CRISPR/Cas gene-editing for cardiovascular diseases. Dr Mostafavi received his PhD in Chemical Engineering (with a focus on Biomedical Engineering and Regenerative Medicine) from Northeastern University, Boston, MA. During his doctoral training, he received several prestigious awards. He has also received training at Harvard Medical School on engineering and development. He also serves as a verified peer-reviewer for over 25 different high-impact journals from prestigious publishers such as Springer Nature, Elsevier, Cell Press, Wiley, Taylor & Francis, Dove Press, PLOS, IOPscience, etc. His scholarly work consists of > 65 publications with an H-index of 22 (i10-index= 35) on Google Scholar Profile. He currently serves on the editorial board of a few biomedical and biotechnological journals, including Dove Medical Press International Journal of Nanomedicine (IF=6.4, Q1), Nature Scientific Reports (IF=4.379), Springer Nature Nanostructure in Chemistry (IF=6.39, Q1), MDPI Functional Biomaterials, BMC Biomedical Engineering & BMC Biotechnology, etc. He also contributed to 10 book chapters and was selected as the editor of several books.